https://doi.org/10.48047/AFJBS.6.10.2024.6711-6743

African Journal of Biological Sciences

Journal homepage: http://www.afjbs.com

Research Paper Open Access

The Promise of Gene Editing Technologies in Precision Medicine: CRISPR-Cas9 Applications in Pharmacology

Sudhir Kumar[1], Shaweta Sharma[2], Akhil Sharma[3], Akanksha Sharma[3], Sunita[4], Pankaj Agrawal[5*]

[1]Faculty of Pharmaceutical Sciences, DAV University, Jalandhar
[2]School of Medical and Allied Sciences, Galgotias University, Yamuna Expressway, Gautam Buddha Nagar, Uttar Pradesh-201310, India
[3]R. J. College of Pharmacy, 2HVJ+567, Raipur, Gharbara, Tappal, Khair, Uttar Pradesh 202165
[4]Metro College of Health Sciences and Research, Greater Noida
[*5]Guru Gobind Singh Indraprastha University Govt of NCT of Delhi Sector 16C Dwarka New Delhi 110078
Corresponding author details: Dr. Pankaj Agrawal, Email Id: pankajggsipu@gmail.com

Volume 6, Issue 10, May 2024

Received: 09 May 2024

Accepted: 19 June 2024

Published: 08 July 2024

doi: 10.48047/AFJBS.6.10.2024.6711-6743

Abstract: Gene editing technologies, particularly CRISPR-Cas9, have revolutionized precision medicine by offering unprecedented capabilities in manipulating the genome with high specificity and efficiency. This review article explores the promise of CRISPR-Cas9 in pharmacology, emphasizing its transformative potential. The article begins with an introduction to gene editing, providing a comprehensive overview of CRISPR-Cas9 technology, its historical development, and its mechanism of action involving guide RNA and the Cas9 enzyme. It highlights the technology's advantages and limitations compared to other gene editing methods. CRISPR-Cas9's applications in drug discovery and development are examined, showcasing its role in identifying new drug targets, high-throughput screening, functional genomics, and enhancing drug efficacy while minimizing off-target effects. The review delves into personalized medicine, illustrating how CRISPR-Cas9 tailors treatments based on individual genetic profiles and utilizes predictive modeling and simulation. Additionally, the technology's potential in addressing drug resistance is discussed, including mechanisms of resistance and strategies for reversing it using CRISPR-Cas9. The article further explores the treatment of genetic diseases, focusing on monogenic disorders like sickle cell anemia, cystic fibrosis, and muscular dystrophy, as well as polygenic disorders. It covers cancer treatment advancements, such as targeting oncogenes and tumor suppressor genes, enhancing immunotherapy, and improving CAR-T cell therapy. CRISPR-Cas9's role in developing antiviral therapies and combatting antibiotic resistance is also highlighted. Ethical and regulatory considerations, including germline versus somatic editing, off-target effects, and the regulatory landscape, are critically analyzed. Emerging technologies, such as base and prime editing, and the integration of AI and machine learning, are discussed alongside future challenges and directions. This review underscores CRISPR-Cas9's transformative potential in pharmacology and precision medicine.

Keywords: CRISPR-Cas9, gene editing technology, precision medicine, personalized medicine, predictive modelling, simulation, sickle cell anemia, cystic fibrosis, muscular dystrophy, polygenic disorders, oncogenes, tumor suppressor genes, immunotherapy, CAR-T cell therapy

Introduction

Gene editing technologies have undergone significant advancements over the past few decades, with CRISPR-Cas9 emerging as a revolutionary tool in the field. Gene editing involves making precise changes to the DNA sequence within a genome, enabling scientists to correct mutations, study gene functions, and develop targeted therapies. The development of gene editing technologies has progressed from earlier methods, such as zinc finger nucleases and TALENs, to the more efficient and versatile CRISPR-Cas9 system. CRISPR-Cas9, derived from the adaptive immune system of bacteria, has transformed gene editing due to its simplicity, precision, and cost-effectiveness (Lafountaine et al., 2015).

CRISPR-Cas9 technology utilizes a guide RNA (gRNA) to direct the Cas9 enzyme to a specific DNA sequence, where it induces a double-strand break. This break can be repaired by the cell's natural repair mechanisms, either by non-homologous end joining (NHEJ), which often results in gene disruption, or by homology-directed repair (HDR), which can introduce precise genetic changes. This mechanism allows for targeted modifications in the genome, making CRISPR-Cas9 a powerful tool for research and therapeutic applications. The technology has been widely adopted due to its ability to edit multiple genes simultaneously, its high specificity, and its relatively low cost compared to previous methods (Barman et al., 2020; Safari F. et al., 2017).

The significance of CRISPR-Cas9 in precision medicine is profound. Precision medicine aims to tailor medical treatment to the individual characteristics of each patient, considering their genetic makeup, environment, and lifestyle. CRISPR-Cas9 enables precise editing of disease-causing genes, offering the potential to correct genetic mutations at their source. This capability opens new avenues for treating a wide range of genetic disorders, including monogenic diseases like cystic fibrosis and sickle cell anemia, as well as complex conditions such as cancer and infectious diseases. By enabling targeted gene therapies, CRISPR-Cas9 aligns with the goals of precision medicine to provide more effective and personalized treatments (Rao, 2022; Wang et al., 2017).

This review aims to explore the promise of CRISPR-Cas9 in pharmacology, focusing on its applications in drug discovery, personalized medicine, and overcoming drug resistance. Additionally, it addresses the ethical and regulatory challenges associated with gene editing, and discusses emerging technologies and future directions. By examining the current state and future potential of CRISPR-Cas9, this review highlights its transformative impact on the field of precision medicine.

Overview of CRISPR-Cas9

History and Development

"Table 1" provides a concise summary of the history and development of CRISPR-Cas9.

Table 1. Summary of history and development of CRISPR-Cas9.

Year	History and Development
1980s	CRISPR sequences identified in bacterial genomes, but function unknown (Barrangou & Horvath, 2017).
Early 2000s	Francisco Mojica and other researchers discover CRISPR sequences are part of bacterial immune defense (Kumar et al., 2024).
2005-2010	Studies reveal CRISPR sequences store viral genetic information and Cas proteins cut viral DNA (Tripathi et al., 2023).
2012	Jennifer Doudna and Emmanuelle Charpentier demonstrate programmable CRISPR-Cas9 system for precise DNA targeting (Charpentier, 2017).
2013	First successful demonstration of CRISPR-Cas9 in human cells and various organisms (Jiang & Doudna, 2017).
2014-2015	Advances in improving specificity and reducing off-target effects; development of high-fidelity Cas9 variants (Chapman et al., 2017).
2016-Present	Emergence of base and prime editing techniques; expanded applications in research, agriculture, and therapeutics (Cook et al., 2017).
2020	Nobel Prize in Chemistry awarded to Doudna and Charpentier for CRISPR-Cas9 (Farhud & Zarif-Yeganeh, 2020).
Current Focus	Enhancing precision, reducing off-target effects, ethical and regulatory considerations, and expanding clinical applications (Luan et al., 2018).

Mechanism of Action

CRISPR-Cas9 operates through a precise mechanism involving two main components: the guide RNA (gRNA) and the Cas9 enzyme. The guide RNA is a synthetic RNA molecule designed to be complementary to a specific target sequence within the DNA of the organism being modified. This sequence is typically 20 nucleotides long and is located adjacent to a protospacer adjacent motif (PAM), a short sequence required for Cas9 recognition and binding (Filippova et al., 2019).

The Cas9 enzyme, a CRISPR-associated endonuclease, acts as a molecular scissors guided by the gRNA. Once the gRNA binds to the target DNA sequence through complementary base pairing, Cas9 undergoes a conformational change that allows it to cleave both strands of the DNA at a precise location near the PAM sequence. This creates a double-strand break (DSB) in the DNA molecule (Ryan et al., 2018).

After the DSB is created, the cell's natural repair mechanisms come into play. Non-homologous end joining (NHEJ) is a common repair pathway that can introduce insertions or deletions (indels) at the break site, disrupting the gene's function. Alternatively, homology-directed repair (HDR) can be utilized in the presence of a donor DNA template, allowing for precise editing of the DNA sequence by incorporating new genetic information. The CRISPR-Cas9 mechanism of action enables targeted and precise modifications to the genome of living organisms, making it a powerful tool for genetic research, biotechnology, and potential therapeutic applications (Willmann, 2020).

Comparison with Other Gene Editing Technologies

CRISPR-Cas9 has revolutionized gene editing due to its distinct advantages over previous technologies such as zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs) (Ferreira & Choupina, 2022). A comparison highlighting the differences are summarized in “Table 2”.

Table 2. CRISPR-Cas9 comparison with other gene editing technologies.

Aspect	CRISPR-Cas9	Zinc Finger Nucleases (ZFNs)	Transcription Activator-Like Effector Nucleases (TALENs)
Mechanism	Uses guide RNA to direct Cas9 enzyme to target DNA sequence(Doetschman & Georgieva, 2017)	Uses engineered zinc finger proteins to bind and cut DNA (Berridge et al., 2020)	Uses custom-designed TAL effector proteins to bind and cut DNA (Khan et al., 2017)
Targeting	High specificity due to sequence-specific	Specificity dependent on the design of zinc finger proteins	Specificity dependent on the design of TAL effector proteins

	gRNA (V. Singh et al., 2017)		
Ease of Design	Relatively easy to design and implement	Complex design process (Bolukbasi, 2024)	Complex design process (T. S. Smith, 2018)
Flexibility	Can target multiple genes simultaneously (Vakulskas & Behlke, 2019)	Limited flexibility	Limited flexibility
Efficiency	Highly efficient in inducing double-strand breaks (DSBs)	Variable efficiency depending on the design and context (Guha et al., 2017)	Variable efficiency depending on the design and context (Losito, 2022)
Off-Target Effects	Potential for off-target effects, mitigated by improved variants (Xue & Greene, 2021)	Potential for off-target effects	Potential for off-target effects (P. Singh, 2018)
Cost	Relatively cost-effective	Expensive due to protein engineering costs (Periwal, 2017)	Expensive due to protein engineering costs
Applications	Broad range of applications in research and therapeutics (Zischewski et al., 2017)	Used primarily in research; therapeutic applications limited (Davies et al., 2017)	Used primarily in research; therapeutic applications limited (Scholarship@western et al., 2017)

Advantages and Limitations

CRISPR-Cas9 offers several distinct advantages in gene editing. Its hallmark precision stems from the ability to target specific DNA sequences using guide RNA (gRNA), minimizing off-target effects typical of earlier technologies like zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs). This precision allows for targeted modifications with high efficiency, facilitating gene knockout or insertion more effectively than previous

methods. CRISPR-Cas9's versatility extends to targeting multiple genes simultaneously, enabling complex genetic studies and potentially enhancing treatments for multifactorial diseases. Moreover, its relative ease of use and cost-effectiveness have democratized genetic research, making it accessible across various organisms and supporting diverse biotechnological applications (Afolabi et al., 2021).

However, CRISPR-Cas9 does have limitations. Despite improvements, off-target effects remain a concern, where unintended genetic changes can occur at sites resembling the target sequence. Variability in efficiency across different target sequences and cell types also affects its reliability in experimental settings. Delivery into target cells, particularly in vivo, poses another significant challenge for therapeutic applications. Ethical considerations surrounding germline editing and regulatory complexities further complicate its transition from research to clinical use. Addressing these challenges requires ongoing refinement of CRISPR-Cas9 technologies, including improved delivery methods, enhanced specificity, and robust regulatory frameworks to ensure safe and ethical use in biomedical contexts (Mengstie & Wondimu, 2021).

CRISPR-Cas9 in Drug Discovery and Development

CRISPR-Cas9 has revolutionized drug discovery and development by facilitating several key processes which sis summarized in “figure 1”.



Figure 1. CRISPR-Cas9 role in drug discovery and development

Identification of New Drug Targets

CRISPR-Cas9 revolutionizes the identification of new drug targets by allowing researchers to systematically interrogate the function of genes implicated in disease pathways. Through precise gene editing, CRISPR-Cas9 enables the creation of cellular models where specific genes can be selectively activated or deactivated. This approach helps elucidate the roles these genes play in disease progression and response to therapeutic agents. By pinpointing critical genetic targets that influence disease mechanisms, CRISPR-Cas9 accelerates the discovery of potential drug targets. Its ability to manipulate genes with high specificity and efficiency makes CRISPR-Cas9 an invaluable tool in advancing precision medicine and drug development, offering new insights into complex diseases and paving the way for more targeted therapeutic interventions (H. Li et al., 2020; Rabaan et al., 2023).

High-throughput Screening

High-throughput screening (HTS) is significantly enhanced by CRISPR-Cas9, revolutionizing the efficiency and scope of genetic and drug discovery research. CRISPR-Cas9 enables HTS by facilitating rapid and systematic screening of large libraries of genetic elements, such as

gRNAs targeting specific genes or regulatory regions. This approach allows researchers to quickly assess the functional impact of genetic modifications across numerous genes simultaneously, accelerating the identification of potential therapeutic targets and drug candidates. By streamlining the screening process, CRISPR-Cas9 not only improves the speed and cost-effectiveness of identifying crucial genetic interactions and drug responses but also enhances the scalability and precision of HTS methodologies (Chan et al., 2022; Zhu, 2022).

Functional Genomics

Functional genomics, empowered by CRISPR-Cas9, revolutionizes the study of gene function and regulation within biological systems. CRISPR-Cas9 enables precise manipulation of gene expression by either disrupting or enhancing specific genes in cellular models. This capability allows researchers to systematically explore how individual genes contribute to biological processes, disease states, and drug responses. By uncovering gene functions and interactions on a genome-wide scale, CRISPR-Cas9 facilitates the discovery of novel biomarkers and therapeutic targets. Its application in functional genomics provides valuable insights into the molecular mechanisms underlying complex diseases, paving the way for more targeted and personalized approaches to diagnostics and therapeutics (Aljabali et al., 2024; Eid & Mahfouz, 2016).

Enhancing Drug Efficacy

CRISPR-Cas9 enables the validation and optimization of drug targets by precisely editing genes involved in disease pathways, ensuring that potential therapeutic targets are thoroughly studied and validated before clinical trials. Secondly, CRISPR-Cas9 allows for the creation of more accurate disease models by introducing specific genetic mutations relevant to patient populations, thereby improving the predictive power of preclinical studies and reducing the likelihood of clinical trial failures. Thirdly, by facilitating the study of drug interactions and mechanisms of action at a molecular level, CRISPR-Cas9 aids in the development of personalized treatment strategies tailored to individual genetic profiles (T. Li et al., 2023; Macarrón Palacios et al., 2024).

Reducing Off-target Effects

Reducing off-target effects is a critical goal in CRISPR-Cas9 research, and several strategies have been developed to address this challenge. Enhanced specificity variants of Cas9 enzymes, such as high-fidelity Cas9 variants, have been engineered to minimize off-target effects by

reducing binding to sequences that differ slightly from the target site. Additionally, bioinformatics tools have been employed to predict potential off-target sites and guide experimental design to avoid unintended genetic alterations. Optimizing the design of guide RNAs (gRNAs) to improve specificity and using truncated gRNAs that reduce the probability of off-target binding further contribute to mitigating off-target effects. Continued advancements in CRISPR-Cas9 technology aim to enhance its precision and safety, ensuring that therapeutic applications can achieve the desired genetic modifications while minimizing unintended consequences (Mengstie et al., 2024; L. Zhang et al., 2023).

Personalized Medicine

Personalized medicine involves tailoring medical treatment to individual characteristics of each patient. This approach takes into account factors such as genetic makeup, biomarkers, lifestyle, and environmental influences to optimize efficacy and minimize adverse effects of treatments. The shift towards personalized medicine marks a departure from the traditional one-size-fits-all approach, aiming to deliver more precise and targeted therapies that align with the unique biological profiles of patients (Mathur & Sutton, 2017).

CRISPR-Cas9 in Tailoring Treatments

CRISPR-Cas9 holds significant promise for advancing personalized medicine by enabling precise genetic modifications tailored to individual patients. In the context of therapeutic applications, CRISPR-Cas9 can be utilized to correct disease-causing mutations in patient-specific cells or to create disease models that mimic the genetic background of individual patients. This capability opens avenues for developing customized therapies that address the underlying genetic causes of diseases, potentially offering more effective treatment options with reduced side effects (Davis et al., 2024).

Predictive Modeling and Simulation

Predictive modeling and simulation are integral to the advancement of personalized medicine, allowing researchers to predict treatment outcomes based on individual patient data and genetic profiles. CRISPR-Cas9 facilitates this process by enabling the creation of accurate disease models that incorporate specific genetic mutations relevant to patient populations. These models can be used to simulate the effects of potential treatments in silico, predicting how different therapies may interact with an individual's genetic background and informing clinical decision-making. By integrating CRISPR-Cas9 technology with predictive modeling,

personalized medicine aims to optimize treatment strategies, improve patient outcomes, and pave the way for more precise and effective healthcare interventions tailored to the individual variability observed in patient populations (Dixit et al., 2023).

Addressing Drug Resistance

Drug resistance poses a significant challenge in medicine, where pathogens or cancer cells adapt to evade the effects of therapeutic treatments. Understanding the mechanisms underlying drug resistance is crucial for developing strategies to overcome or reverse it (Mansoori et al., 2017).

Mechanisms of Drug Resistance

CRISPR-Cas9 itself does not exhibit drug resistance mechanisms in the traditional sense observed in pathogens or cancer cells. In research and therapeutic applications using CRISPR-Cas9, the potential for resistance can arise in several ways:

Off-Target Effects

CRISPR-Cas9 can inadvertently edit unintended genomic loci that may confer resistance to therapeutic interventions. This unintended editing could lead to genetic changes that alter drug targets or cellular pathways, reducing the effectiveness of treatments (W. Liu et al., 2021).

Immune Response

In therapeutic settings, the immune system may recognize CRISPR-Cas9 components as foreign and mount an immune response against them. This immune response could limit the duration or effectiveness of CRISPR-Cas9-mediated treatments (Rasul et al., 2022).

Repair Mechanisms

Cells have inherent DNA repair mechanisms that may repair CRISPR-Cas9-induced double-strand breaks (DSBs) in a way that renders them resistant to subsequent editing attempts. This can complicate efforts to achieve sustained and precise genetic modifications using CRISPR-Cas9.

Strategies such as improving specificity, enhancing delivery methods, and developing novel CRISPR-Cas9 variants with reduced off-target effects are actively being pursued to address these challenges and maximize the utility of CRISPR-Cas9 in precision medicine and biotechnology (Lampe et al., 2023).

CRISPR-Cas9 in Reversing Resistance

CRISPR-Cas9 offers innovative approaches to address drug resistance by targeting and modifying specific genes involved in resistance mechanisms. Researchers can use CRISPR-Cas9 to investigate the genetic basis of resistance, identifying key genes or mutations that confer resistance to certain drugs. By editing these genes, CRISPR-Cas9 can potentially reverse or mitigate drug resistance, restoring sensitivity to treatments. Moreover, CRISPR-Cas9 enables the development of new therapeutic strategies aimed at overcoming resistance mechanisms, such as enhancing drug delivery or targeting alternative pathways to bypass resistance mechanisms altogether. This approach holds promise for improving treatment outcomes and prolonging the effectiveness of existing therapies in combating drug-resistant diseases (Chen & Zhang, 2018; Ekwebelem et al., 2021).

Applications in Treating Genetic Diseases

Monogenic Disorders

CRISPR-Cas9 holds tremendous potential for treating genetic diseases, particularly monogenic disorders characterized by mutations in a single gene. CRISPR-Cas9 could be applied to treat some notable monogenic disorders which is described below.

Sickle Cell Anemia

CRISPR-Cas9 offers a groundbreaking approach to potentially cure sickle cell anemia by directly targeting the genetic mutation responsible for the disease. Sickle cell anemia is caused by a single-point mutation in the HBB gene, which encodes the beta-globin protein. This mutation results in the production of abnormal hemoglobin (HbS), leading to the characteristic sickle-shaped red blood cells and a range of associated health complications (Hardouin et al., 2023).

The strategy involves using CRISPR-Cas9 to edit hematopoietic stem cells (HSCs) extracted from the patient. Specifically, CRISPR-Cas9 is programmed to target the mutated sequence in the HBB gene and induce a double-strand break (DSB) at the site of the mutation. This DSB activates the cell's natural DNA repair mechanisms, such as non-homologous end joining (NHEJ) or homology-directed repair (HDR) (Chehelgerdi et al., 2024).

In the case of sickle cell anemia, the goal is to repair the mutation in a way that restores the normal function of the HBB gene, allowing for the production of normal hemoglobin (HbA)

instead of the abnormal HbS. This approach aims to correct the underlying genetic defect at the root of the disease, potentially offering a permanent cure rather than just managing symptoms (Young, 2023).

Cystic Fibrosis

CRISPR-Cas9 holds promise for treating cystic fibrosis (CF), a genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. CFTR encodes a protein that regulates chloride ion transport across cell membranes, crucial for maintaining proper fluid balance in organs such as the lungs, pancreas, and digestive system (Brodlie et al., 2015).

In the context of CF treatment, CRISPR-Cas9 could potentially correct CFTR mutations in patient-derived cells, particularly airway epithelial cells or organoids. By precisely editing the defective CFTR gene, CRISPR-Cas9 aims to restore normal protein function and chloride ion transport. This could alleviate the buildup of thick and sticky mucus in the lungs and other affected organs, a hallmark of CF that leads to recurrent infections and progressive lung damage (Hodges & Conlon, 2019).

Muscular Dystrophy

CRISPR-Cas9 holds promise in the treatment of muscular dystrophy, a group of genetic disorders characterized by progressive muscle weakness and degeneration. One of the most common forms, Duchenne muscular dystrophy (DMD), is caused by mutations in the dystrophin gene (DMD), which leads to the absence or dysfunction of the dystrophin protein essential for muscle integrity (Agrawal et al., 2023).

The potential role of CRISPR-Cas9 in treating muscular dystrophy involves targeting and correcting these genetic mutations in muscle cells or muscle progenitor cells. By introducing precise edits to the DMD gene, CRISPR-Cas9 aims to restore the production of functional dystrophin protein. This could potentially halt or slow down the progression of muscle degeneration and improve muscle function in affected individuals (Hotta, 2015).

Polygenic Disorders

Polygenic disorders are complex conditions influenced by variations in multiple genes, each contributing small effects to the overall risk of developing the disorder. Unlike monogenic disorders, which result from mutations in a single gene, polygenic disorders arise from the

combined effects of genetic variations across the genome, as well as interactions with environmental factors (Fullerton & Nurnberger, 2019).

CRISPR-Cas9 technology presents unique challenges and opportunities in the context of polygenic disorders. While CRISPR-Cas9 is highly effective in editing specific genes associated with monogenic diseases, targeting multiple genes simultaneously to address polygenic disorders is more complex. However, CRISPR-Cas9 can still play a crucial role in studying polygenic disorders by enabling researchers to systematically edit and investigate the functions of multiple genes implicated in disease pathways (Lewis & Vassos, 2020).

An approach involves using CRISPR-Cas9 to create cellular or animal models that mimic the genetic complexity observed in polygenic disorders. These models can help researchers unravel the interactions between different genetic variants and environmental factors, shedding light on disease mechanisms and potential therapeutic targets. Moreover, CRISPR-Cas9-based genome-wide screening approaches, such as CRISPR activation (CRISPRa) or interference (CRISPRi), can be employed to identify key genes and regulatory elements contributing to disease susceptibility or progression (Saito, 2011).

Cancer Treatment

CRISPR-Cas9 holds promise in revolutionizing cancer treatment through various innovative approaches which is discussed below.

Targeting Oncogenes and Tumor Suppressor Genes

Targeting oncogenes and tumor suppressor genes using CRISPR-Cas9 represents a powerful strategy in cancer research and therapy. Oncogenes are genes that promote cancer growth when mutated or overexpressed, while tumor suppressor genes typically function to inhibit tumor formation. CRISPR-Cas9 enables precise editing of these genes in cancer cells, offering several potential applications (White & Khalili, 2016).

Knockout of Oncogenes

CRISPR-Cas9 can be used to disrupt oncogenic mutations or overexpressed oncogenes in cancer cells. By introducing targeted genetic modifications, CRISPR-Cas9 aims to inhibit the aberrant signaling pathways that drive cancer cell proliferation and survival (Alinejad et al., 2023).

Restoration of Tumor Suppressor Function

In cancers where tumor suppressor genes are mutated or silenced, CRISPR-Cas9 can potentially restore normal gene function. This may involve correcting mutations or enhancing the expression of tumor suppressor genes to promote their anti-cancer effects, such as inducing apoptosis or inhibiting cell cycle progression (B. Liu et al., 2019).

Functional Genomics Studies

CRISPR-Cas9 facilitates the study of oncogenes and tumor suppressor genes by creating knockout or knock-in models in cellular or animal systems. These models help researchers understand the roles of specific genes in cancer development and progression, elucidating underlying mechanisms and identifying new therapeutic targets (D. J. Smith et al., 2024).

Drug Resistance Studies

By editing oncogenes and tumor suppressor genes in cancer cells, CRISPR-Cas9 can also be used to investigate mechanisms of drug resistance. This includes studying how genetic alterations affect responses to targeted therapies or chemotherapy, potentially guiding the development of new treatment strategies to overcome resistance (Rangel et al., 2024).

CRISPR-Cas9 in Immunotherapy

CRISPR-Cas9 is poised to revolutionize immunotherapy, particularly in the context of cancer treatment, by enhancing the precision and effectiveness of therapeutic approaches that harness the immune system to target tumors. The roles of CRISPR-Cas9 in immunotherapy are summarized in “figure 2” and described below.



Figure 2. Role of CRISPR-Cas9 in immunotherapy

Engineering CAR-T Cells

CRISPR-Cas9 is used to genetically modify patient-derived T cells to express chimeric antigen receptors (CARs) that recognize specific tumor antigens. This customization allows CAR-T cells to target and kill cancer cells more effectively, potentially improving treatment outcomes for patients with hematologic malignancies and solid tumors (Kavousinia et al., 2024).

Enhancing T-cell Function

CRISPR-Cas9 can be employed to edit genes in T cells that regulate their function and activity. For instance, knocking out genes such as PD-1 or CTLA-4, which are involved in immune checkpoint pathways, can enhance T-cell activation and persistence within the tumor microenvironment, overcoming immune suppression and promoting anti-tumor immunity (Kim et al., 2021).

Altering Immune Cell Signaling

Researchers use CRISPR-Cas9 to study immune cell signaling pathways critical for immune response regulation. By editing genes involved in these pathways, such as cytokines or receptors, CRISPR-Cas9 enables the manipulation of immune cell behavior to improve their anti-tumor activity and overall effectiveness in immunotherapy (Buquicchio & Satpathy, 2021).

Creating Universal CAR-T Cells

CRISPR-Cas9 facilitates the development of universal CAR-T cell therapies by editing genes involved in immune recognition or rejection. This includes disrupting major histocompatibility complex (MHC) molecules or introducing universal safety switches, enabling CAR-T cells to be used across different patients without inducing graft-versus-host disease or immune rejection (C. Li et al., 2020).

CRISPR Screening in Immunotherapy

CRISPR-Cas9-based genome-wide screening approaches, such as CRISPR activation (CRISPRa) or interference (CRISPRi), are utilized to identify novel therapeutic targets or immune regulators that can enhance the efficacy of immunotherapy approaches (Z. Liu et al., 2023).

CAR-T Cell Therapy Enhancements

CRISPR-Cas9 has emerged as a transformative tool for enhancing CAR-T cell therapy, a promising approach in cancer treatment that involves genetically modifying a patient's T cells to target and destroy cancer cells. Various ways CRISPR-Cas9 is being utilized to improve CAR-T cell therapy (Tao et al., 2024).

Enhancing T-cell Efficacy and Persistence

CRISPR-Cas9 enables precise genetic modifications in T cells to enhance their anti-tumor activity and persistence within the body. This includes disrupting genes that inhibit T-cell function, such as PD-1 or CTLA-4, which are immune checkpoint inhibitors. By knocking out these genes, CRISPR-Cas9 can prevent T-cell exhaustion and enhance their ability to recognize and kill cancer cells effectively (Wei et al., 2023).

Improving T-cell Specificity

CRISPR-Cas9 can be used to engineer CAR-T cells with enhanced specificity for tumor antigens. Researchers can design CAR constructs that precisely target tumor-specific antigens while minimizing off-target effects on healthy tissues. This customization enhances the safety and efficacy of CAR-T cell therapy by ensuring that engineered T cells selectively target cancer cells (Dimitri et al., 2022).

Introducing Safety Mechanisms

CRISPR-Cas9 facilitates the incorporation of safety mechanisms into CAR-T cells to mitigate potential risks, such as cytokine release syndrome or off-target effects. For example,

researchers can integrate suicide genes or safety switches into CAR-T cells using CRISPR-Cas9, allowing for the controlled elimination of engineered T cells if adverse reactions occur (Huang et al., 2020).

Creating Universal CAR-T Cells

CRISPR-Cas9 plays a crucial role in developing universal CAR-T cell therapies that can be administered to multiple patients without triggering immune rejection. By editing genes involved in immune recognition, such as MHC molecules, CRISPR-Cas9 enables the creation of off-the-shelf CAR-T cell products that are broadly applicable and readily available for treatment (Song et al., 2024).

Engineering Resistance to Immunoevasion Mechanisms

Cancer cells often employ various immunoevasion mechanisms to evade immune detection and destruction. CRISPR-Cas9 enables researchers to study and edit genes involved in these mechanisms, potentially enhancing CAR-T cell therapy's ability to overcome tumor resistance and improve treatment outcomes (H. Zhang et al., 2021).

Precision Oncology: Tailoring Treatments

Precision oncology aims to customize cancer treatment strategies based on individual genetic profiles, tumor characteristics, and other molecular markers. CRISPR-Cas9 technology plays a crucial role in advancing precision oncology by enabling precise genome editing and functional genomic studies. CRISPR-Cas9 contributes to tailoring treatments in precision oncology which is discussed below.

Identification of Therapeutic Targets

CRISPR-Cas9 facilitates the identification and validation of specific genetic mutations or alterations that drive cancer development and progression. Researchers use CRISPR-Cas9 to create cellular and animal models with precise mutations, enabling the study of gene function and its impact on tumor biology. This knowledge helps identify potential therapeutic targets that can be exploited for personalized treatment approaches (Yang et al., 2021).

Personalized Therapy Development

CRISPR-Cas9 allows for the development of personalized therapeutic strategies tailored to individual patients. By editing patient-derived cells or tumor organoids, researchers can test the efficacy of potential therapies in models that closely mimic the genetic makeup and

behavior of the patient's tumor. This approach helps predict treatment responses and optimize therapeutic regimens based on specific genetic profiles and tumor characteristics (Ding et al., 2023).

Drug Sensitivity and Resistance Studies

CRISPR-Cas9-based genome editing facilitates the study of drug sensitivity and resistance mechanisms in cancer cells. Researchers can systematically edit genes involved in drug metabolism, resistance pathways, or DNA repair mechanisms to understand how tumors respond to various treatments. This information guides the selection of the most effective therapies and helps predict and overcome resistance mechanisms that may arise during treatment (Shirani-Bidabadi et al., 2023).

Functional Genomics and Biomarker Discovery

CRISPR-Cas9 enables high-throughput functional genomic screening to identify novel biomarkers associated with cancer progression or treatment response. By editing genes across the genome, researchers can uncover genetic interactions, signaling pathways, and biological processes that influence tumor behavior and treatment outcomes. This knowledge contributes to the discovery of new biomarkers for patient stratification and prognosis in precision oncology (Katti et al., 2022).

Advancing Combination Therapies

CRISPR-Cas9 supports the development of combination therapies by elucidating synergistic interactions between targeted agents, immunotherapies, and other treatment modalities. Researchers can use CRISPR-Cas9 to investigate the effects of combining therapies targeting different pathways or cellular processes, aiming to maximize therapeutic efficacy and minimize toxicity in personalized treatment regimens (Yin et al., 2021).

Infectious Diseases

Developing Antiviral Therapies

CRISPR-Cas9-based strategies for developing antiviral therapies primarily focus on targeting viral genomes and disrupting their replication cycles. Key applications include:

Viral Genome Editing

CRISPR-Cas9 can be programmed to target and cleave specific sequences within viral genomes, rendering viruses inactive or reducing their ability to replicate. This approach has been explored in targeting DNA and RNA viruses, including HIV, herpesviruses, and influenza viruses (Najafi et al., 2022).

Viral Gene Regulation

CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) techniques can modulate the expression of viral genes essential for viral replication and pathogenesis. By targeting viral promoters or enhancers, CRISPR-Cas9 can suppress viral gene expression or enhance host immune responses against viral infections (Call & Andrews, 2022).

Viral Resistance Studies

CRISPR-Cas9 enables researchers to create viral-resistant cell lines or animal models by editing host genes involved in viral entry, replication, or immune evasion mechanisms. These models help study viral pathogenesis and evaluate potential targets for antiviral therapies (Z. Zhang et al., 2022).

Combatting Antibiotic Resistance

CRISPR-Cas9 offers innovative approaches to combat antibiotic resistance, a growing global health concern which is described below.

Genetic Modification of Pathogens

CRISPR-Cas9 can be used to genetically modify bacterial pathogens, targeting genes responsible for antibiotic resistance mechanisms. This includes disrupting genes encoding antibiotic resistance enzymes, efflux pumps, or modifying regulatory elements that control resistance gene expression (van Esse et al., 2020).

Diagnostic Tools

CRISPR-based diagnostics, such as SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing), leverage CRISPR-Cas systems for rapid and sensitive detection of antibiotic-resistant pathogens. These methods enable early identification of resistant strains, guiding appropriate treatment decisions and infection control measures (Kaminski et al., 2021).

Phage Therapy Development

CRISPR-Cas9 is utilized in engineering bacteriophages (viruses that infect bacteria) to specifically target and kill antibiotic-resistant bacterial strains. By editing phage genomes, researchers can enhance phage host range, virulence, and efficacy against drug-resistant bacteria, offering potential alternatives to traditional antibiotics (Khambhati et al., 2023).

Emerging Technologies

Emerging technologies are propelling CRISPR-Cas9 beyond its initial capabilities, paving the way for more precise and versatile genome editing applications. Key advancements include base editing, prime editing, and the integration of AI and machine learning (Ansori et al., 2023).

Advancements in CRISPR Technology

CRISPR-Cas9 has evolved beyond its original genome-editing capabilities, with advancements enhancing its efficiency, specificity, and versatility. Researchers have developed various CRISPR systems and tools, such as CRISPR interference (CRISPRi) for gene regulation and CRISPR activation (CRISPRa) for gene activation. These advancements enable targeted manipulation of gene expression without altering DNA sequences permanently (Moon et al., 2019).

Base Editing

Base editing expands CRISPR-Cas9's toolkit by enabling precise changes to single DNA bases (nucleotides) without causing double-stranded breaks. Base editors combine a catalytically impaired Cas protein with a deaminase enzyme to convert one base pair directly into another, such as converting cytosine (C) to thymine (T) or adenine (A) to guanine (G). This approach offers potential applications in correcting point mutations associated with genetic disorders or optimizing traits in agricultural biotechnology (Ricroch et al., 2024).

Prime Editing

Prime editing represents a significant leap forward in genome editing precision. This technology combines a catalytically impaired Cas protein with an engineered reverse transcriptase enzyme and a prime editing guide RNA (pegRNA). Prime editing enables precise insertion, deletion, or substitution of target DNA sequences, surpassing the limitations of traditional CRISPR-Cas9 approaches by offering greater flexibility and reducing off-target effects (W. Zhang et al., 2013).

Integrating AI and Machine Learning

The integration of artificial intelligence (AI) and machine learning significantly enhances CRISPR-Cas9's capabilities across multiple fronts. AI algorithms analyze extensive genomic datasets to predict precise CRISPR-Cas9 target sites, thereby enhancing efficiency and minimizing off-target effects. Machine learning algorithms play a crucial role in designing novel CRISPR systems by optimizing their specificity, activity levels, and delivery mechanisms, advancing their effectiveness in genome editing applications. Furthermore, AI-driven approaches aid in interpreting CRISPR-Cas9 screening data in functional genomics studies, facilitating the identification of genes implicated in specific biological processes and disease pathways. Together, these AI and machine learning advancements are revolutionizing CRISPR-Cas9 technology, accelerating its potential impact in diverse fields from medicine to biotechnology (Bhat et al., 2022).

Ethical and Regulatory Considerations

Ethical and regulatory considerations surrounding CRISPR-Cas9 and gene editing technologies are deeply intertwined with scientific advancements, ethical dilemmas, safety concerns, and evolving regulatory frameworks.

CRISPR-Cas9's precision in editing genomes raises significant ethical implications, particularly in the context of germline editing. Altering germline cells—eggs, sperm, or embryos—can lead to heritable genetic changes that affect future generations. Ethical debates focus on the potential for unintended consequences and the ethical boundaries between therapeutic interventions and enhancements of non-disease traits. Ensuring informed consent from individuals undergoing gene editing procedures, especially in clinical settings, is crucial to uphold autonomy and ethical standards (Dâ€TMSouza et al., 2023).

Distinctions between germline and somatic editing are pivotal in ethical discourse. Germline editing poses ethical concerns due to its heritability and implications for human evolution, while somatic editing targets non-reproductive cells to treat specific individuals without impacting future generations. Safety concerns include off-target effects, where CRISPR-Cas9 may unintentionally edit genomic locations other than the target site, potentially leading to genetic instability or new health risks. Mosaicism, or incomplete editing of all cells within an organism, complicates achieving consistent therapeutic outcomes and understanding long-term effects (Bartkowski B. et al., 2018).

The regulatory landscape for gene editing technologies varies globally, with regulatory agencies like the FDA and EMA assessing safety, efficacy, and ethical implications in clinical

trials and medical practice. Guidelines and moratoriums exist in many countries to navigate ethical and societal concerns surrounding germline editing and specific applications of CRISPR-Cas9. Public perception is influenced by perceptions of risk, safety, ethical implications, and potential misuse of gene editing. Education and awareness play crucial roles in fostering informed societal dialogue and decision-making regarding the responsible deployment of CRISPR-Cas9 and gene editing technologies.

Navigating these complex ethical and regulatory considerations requires balancing potential therapeutic benefits with ethical standards, safety considerations, and societal values, ensuring responsible and equitable use of gene editing technologies for the benefit of humanity (Shinwari et al., 2018).

Challenges and Future Directions

The promise of CRISPR-Cas9 in precision medicine, particularly its applications in pharmacology, faces several significant challenges and presents exciting future directions. Challenges include optimizing delivery methods to target specific tissues or cells effectively, minimizing off-target effects to ensure safety, and addressing ethical and regulatory considerations surrounding gene editing technologies (Behr et al., 2021).

Additionally, the complexity of multifactorial diseases requires a deeper understanding of gene interactions and pathways for effective therapeutic interventions. Future directions involve advancing CRISPR-Cas9 technologies, such as base editing and prime editing, to enhance precision and broaden the scope of treatable genetic disorders. Integrating AI and machine learning to predict CRISPR target sites and interpret genomic data promises to revolutionize personalized medicine approaches (S. V. et al., 2024).

Moreover, exploring CRISPR's potential in developing novel therapies, including gene therapies and immunotherapies, offers new avenues for treating previously incurable conditions. Overcoming these challenges and embracing these future directions holds the potential to realize the full therapeutic promise of CRISPR-Cas9 in transforming pharmacological treatments and advancing precision medicine paradigms (Ravichandran & Maddalo, 2023).

Conclusion

In conclusion, CRISPR-Cas9 stands at the forefront of revolutionizing precision medicine in pharmacology, offering unparalleled potential in treating genetic disorders and advancing

personalized therapies. Its ability to precisely edit genomes holds promise for correcting disease-causing mutations, developing targeted drug therapies, and enhancing treatment efficacy while minimizing adverse effects. However, realizing this promise requires overcoming significant challenges, including refining delivery methods, ensuring safety by mitigating off-target effects, and navigating complex ethical and regulatory landscapes. Looking forward, further research into advanced CRISPR technologies like base editing and prime editing, coupled with the integration of AI and machine learning for target prediction and functional genomics, will expand CRISPR-Cas9's capabilities. These advancements not only pave the way for more effective treatments across a spectrum of diseases but also underscore the transformative potential of gene editing in reshaping the future of pharmacology and precision medicine. As CRISPR-Cas9 continues to evolve, collaboration among scientists, clinicians, regulators, and ethicists will be crucial in harnessing its full potential to improve patient outcomes and redefine therapeutic approaches in the coming years.

Acknowledgement

Authors are highly thankful to their Universities/Colleges to provide library facilities for the literature survey.

References

Afolabi, L. O., Afolabi, M. O., Sani, M. M., Okunowo, W. O., Yan, D., Chen, L., Zhang, Y., & Wan, X. (2021). Exploiting the CRISPR-Cas9 gene-editing system for human cancers and immunotherapy. In *Clinical and Translational Immunology* (Vol. 10, Issue 6). John Wiley and Sons Inc. https://doi.org/10.1002/cti2.1286

Agrawal, P., Harish, V., Mohd, S., Kumar Singh, S., Tewari, D., Tatiparthi, R., Vishwas, S., Sutrapu, S., Dua, K., & Gulati, M. (2023). Role of CRISPR/Cas9 in the treatment of Duchenne muscular dystrophy and its delivery strategies. In *Life Sciences*.

Alinejad, T., Modarressi, S., Sadri, Z., Hao, Z., & Chen, C. S. (2023). Diagnostic applications and therapeutic option of Cascade CRISPR/Cas in the modulation of miRNA in diverse cancers: promises and obstacles. In *Journal of Cancer Research and Clinical Oncology* (Vol. 149, Issue 12, pp. 9557–9575). Springer Science and Business Media Deutschland GmbH. https://doi.org/10.1007/s00432-023-04747-6

Aljabali, A. A. A., El-Tanani, M., & Tambuwala, M. M. (2024). Principles of CRISPR-Cas9 technology: Advancements in genome editing and emerging trends in drug delivery. In

Journal of Drug Delivery Science and Technology (Vol. 92). Editions de Sante. https://doi.org/10.1016/j.jddst.2024.105338

Ansori, A. N. M., Antonius, Y., Susilo, R. J. K., Hayaza, S., Kharisma, V. D., Parikesit, A. A., Zainul, R., Jakhmola, V., Saklani, T., Rebezov, M., Ullah, M. E., Maksimiuk, N., Derkho, M., & Burkov, P. (2023). Application of CRISPR-Cas9 genome editing technology in various fields: A review. In *Narra J* (Vol. 3, Issue 2). Narra Sains Indonesia. https://doi.org/10.52225/narra.v3i2.184

Barman, A., Deb, B., & Chakraborty, S. (2020). A glance at genome editing with CRISPR–Cas9 technology. In *Current Genetics* (Vol. 66, Issue 3, pp. 447–462). Springer. https://doi.org/10.1007/s00294-019-01040-3

Barrangou, R., & Horvath, P. (2017). A decade of discovery: CRISPR functions and applications Access options. In *Nature Microbiology* (Vol. 2). https://www.nature.com/articles/nmicrobiol201792

Bartkowski B. et al. (2018). *Snipping around for food_ Economic, ethical and policy implications of CRISPR_Cas genome editing - ScienceDirect*.

Behr, M., Zhou, J., Xu, B., & Zhang, H. (2021). In vivo delivery of CRISPR-Cas9 therapeutics: Progress and challenges. In *Acta Pharmaceutica Sinica B* (Vol. 11, Issue 8, pp. 2150–2171). Chinese Academy of Medical Sciences. https://doi.org/10.1016/j.apsb.2021.05.020

Berridge, M. V., Herst, P. M., & Grasso, C. (2020). Mitochondrial movement between mammalian cells: An emerging physiological phenomenon. In *The Human Mitochondrial Genome: From Basic Biology to Disease* (pp. 515–546). Elsevier. https://doi.org/10.1016/B978-0-12-819656-4.00020-6

Bhat, A. A., Nisar, S., Mukherjee, S., Saha, N., Yarravarapu, N., Lone, S. N., Masoodi, T., Chauhan, R., Maacha, S., Bagga, P., Dhawan, P., Akil, A. A. S., El-Rifai, W., Uddin, S., Reddy, R., Singh, M., Macha, M. A., & Haris, M. (2022). Integration of CRISPR/Cas9 with artificial intelligence for improved cancer therapeutics. In *Journal of Translational Medicine* (Vol. 20, Issue 1). BioMed Central Ltd. https://doi.org/10.1186/s12967-022-03765-1

Bolukbasi, A. (2024). *Development of Chimeric Cas9 Nucleases for Accurate and Flexible Genome Editing Item Type Doctoral Dissertation*. https://doi.org/10.13028/M26M4Q

Brodlie, M., Haq, I. J., Roberts, K., & Elborn, J. S. (2015). Targeted therapies to improve CFTR function in cystic fibrosis. In *Genome Medicine* (Vol. 7, Issue 1). BioMed Central Ltd. https://doi.org/10.1186/s13073-015-0223-6

Buquicchio, F. A., & Satpathy, A. T. (2021). Interrogating immune cells and cancer with CRISPR-Cas9. In *Trends in Immunology* (Vol. 42, Issue 5, pp. 432–446). Elsevier Ltd. https://doi.org/10.1016/j.it.2021.03.003

Call, S. N., & Andrews, L. B. (2022). CRISPR-Based Approaches for Gene Regulation in Non-Model Bacteria. In *Frontiers in Genome Editing* (Vol. 4). Frontiers Media S.A. https://doi.org/10.3389/fgeed.2022.892304

Chan, Y. T., Lu, Y., Wu, J., Zhang, C., Tan, H. Y., Bian, Z. X., Wang, N., & Feng, Y. (2022). CRISPR-Cas9 library screening approach for anti-cancer drug discovery: overview and perspectives. In *Theranostics* (Vol. 12, Issue 8, pp. 3329–3344). Ivyspring International Publisher. https://doi.org/10.7150/thno.71144

Chapman, J. E., Gillum, D., & Kiani, S. (2017). Approaches to reduce CRISPR off-target effects for safer genome editing. *Applied Biosafety*, *22*(1), 7–13. https://doi.org/10.1177/1535676017694148

Charpentier, E. (2017). Gene Editing and Genome Engineering with CRISPR-Cas9. *Molecular Frontiers Journal*, *01*(02), 99–107. https://doi.org/10.1142/s2529732517400119

Chehelgerdi, M., Chehelgerdi, M., Khorramian-Ghahfarokhi, M., Shafieizadeh, M., Mahmoudi, E., Eskandari, F., Rashidi, M., Arshi, A., & Mokhtari-Farsani, A. (2024). Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy. In *Molecular Cancer* (Vol. 23, Issue 1). BioMed Central Ltd. https://doi.org/10.1186/s12943-023-01925-5

Chen, Y., & Zhang, Y. (2018). Application of the CRISPR/Cas9 System to Drug Resistance in Breast Cancer. In *Advanced Science* (Vol. 5, Issue 6). John Wiley and Sons Inc. https://doi.org/10.1002/advs.201700964

Cook, N., Greenaway, A., & Kirk, N. (2017). *Annotated bibliography: Potential ethical issues and unintended effects of CRISPR gene editing and gene drives for invasive species control*.

Dâ€™Souza, R. F., Mathew, M., & Surapaneni, K. M. (2023). A Scoping Review on the Ethical Issues in the Use of CRISPR-Cas9 in the Creation of Human Disease Models. *JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH*. https://doi.org/10.7860/jcdr/2023/68275.18809

Davies, J. P., Kumar, S., & Sastry-Dent, L. (2017). Chapter Three-Use of Zinc-Finger Nucleases for Crop Improvement. In *Progress in Molecular Biology and Translational Science*.

https://doi.org/./bs.pmbts...https://www.sciencedirect.com/science/article/abs/pii/S1877117317300388

Davis, D. J., Goutham, S., & Yeddula, R. (2024). *CRISPR Advancements for Human Health*.

Dimitri, A., Herbst, F., & Fraietta, J. A. (2022). Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing. In *Molecular Cancer* (Vol. 21, Issue 1). BioMed Central Ltd. https://doi.org/10.1186/s12943-022-01559-z

Ding, S., Liu, J., Han, X., & Tang, M. (2023). CRISPR/Cas9-Mediated Genome Editing in Cancer Therapy. In *International Journal of Molecular Sciences* (Vol. 24, Issue 22). Multidisciplinary Digital Publishing Institute (MDPI). https://doi.org/10.3390/ijms242216325

Dixit, S., Kumar, A., Srinivasan, K., Vincent, P. M. D. R., & Ramu Krishnan, N. (2023). Advancing genome editing with artificial intelligence: opportunities, challenges, and future directions. In *Frontiers in Bioengineering and Biotechnology* (Vol. 11). Frontiers Media SA. https://doi.org/10.3389/fbioe.2023.1335901

Doetschman, T., & Georgieva, T. (2017). Gene Editing with CRISPR/Cas9 RNA-Directed Nuclease. In *Circulation Research* (Vol. 120, Issue 5, pp. 876–894). Lippincott Williams and Wilkins. https://doi.org/10.1161/CIRCRESAHA.116.309727

Eid, A., & Mahfouz, M. M. (2016). Genome editing: The road of CRISPR/Cas9 from bench to clinic. In *Experimental and Molecular Medicine* (Vol. 48, Issue 10). Nature Publishing Group. https://doi.org/10.1038/emm.2016.111

Ekwebelem, O. C., Aleke, J., Ofielu, E., & Nnorom-Dike, O. (2021). Retraction: CRISPR-Cas9 System: A Revolutionary Tool in the Fight Against Antimicrobial Resistance (Infectious Microbes & Diseases). In *Infectious Microbes and Diseases* (Vol. 3, Issue 2, pp. 51–56). Lippincott Williams and Wilkins. https://doi.org/10.1097/IM9.0000000000000049

Farhud, D. D., & Zarif-Yeganeh, M. (2020). CRISPR Pioneers Win 2020 Nobel Prize for Chemistry. In *Iran J Public Health* (Vol. 49, Issue 12). https://creativecommons.org/licenses/by-nc/4.0/

Ferreira, P., & Choupina, A. B. (2022). CRISPR/Cas9 a simple, inexpensive and effective technique for gene editing. *Molecular Biology Reports*, *49*(7), 7079–7086. https://doi.org/10.1007/s11033-022-07442-w

Filippova, J., Matveeva, A., Zhuravlev, E., & Stepanov, G. (2019). Guide RNA modification as a way to improve CRISPR/Cas9-based genome-editing systems. In *Biochimie* (Vol. 167, pp. 49–60). Elsevier B.V. https://doi.org/10.1016/j.biochi.2019.09.003

Fullerton, J. M., & Nurnberger, J. I. (2019). Polygenic risk scores in psychiatry: Will they be useful for clinicians?. In *F1000Research* (Vol. 8). F1000 Research Ltd. https://doi.org/10.12688/f1000research.18491.1

Guha, T. K., Wai, A., & Hausner, G. (2017). Programmable Genome Editing Tools and their Regulation for Efficient Genome Engineering. In *Computational and Structural Biotechnology Journal* (Vol. 15, pp. 146–160). Elsevier B.V. https://doi.org/10.1016/j.csbj.2016.12.006

Hardouin, G., Magrin, E., Corsia, A., Cavazzana, M., Miccio, A., & Semeraro, M. (2023). *Sickle Cell Disease: From Genetics to Curative Approaches*. https://doi.org/10.1146/annurev-genom-120122

Hodges, C. A., & Conlon, R. A. (2019). Delivering on the promise of gene editing for cystic fibrosis. In *Genes and Diseases* (Vol. 6, Issue 2, pp. 97–108). Chongqing University. https://doi.org/10.1016/j.gendis.2018.11.005

Hotta, A. (2015). Genome Editing Gene Therapy for Duchenne Muscular Dystrophy. In *Journal of Neuromuscular Diseases* (Vol. 2, Issue 4, pp. 343–355). IOS Press. https://doi.org/10.3233/JND-150116

Huang, D., Miller, M., Ashok, B., Jain, S., & Peppas, N. A. (2020). CRISPR/Cas systems to overcome challenges in developing the next generation of T cells for cancer therapy. In *Advanced Drug Delivery Reviews* (Vol. 158, pp. 17–35). Elsevier B.V. https://doi.org/10.1016/j.addr.2020.07.015

Jiang, F., & Doudna, J. A. (2017). *CRISPR-Cas9 Structures and Mechanisms*. https://doi.org/10.1146/annurev-biophys

Kaminski, M. M., Abudayyeh, O. O., Gootenberg, J. S., Zhang, F., & Collins, J. J. (2021). CRISPR-based diagnostics. In *Nature Biomedical Engineering* (Vol. 5, Issue 7, pp. 643–656). Nature Research. https://doi.org/10.1038/s41551-021-00760-7

Katti, A., Diaz, B. J., Caragine, C. M., Sanjana, N. E., & Dow, L. E. (2022). CRISPR in cancer biology and therapy. In *Nature Reviews Cancer* (Vol. 22, Issue 5, pp. 259–279). Nature Research. https://doi.org/10.1038/s41568-022-00441-w

Kavousinia, P., Ahmadi, M. H., Sadeghian, H., & Hosseini Bafghi, M. (2024). Therapeutic potential of CRISPR/CAS9 genome modification in T cell-based immunotherapy of cancer. In *Cytotherapy* (Vol. 26, Issue 5, pp. 436–443). Elsevier B.V. https://doi.org/10.1016/j.jcyt.2024.02.014

Khambhati, K., Bhattacharjee, G., Gohil, N., Dhanoa, G. K., Sagona, A. P., Mani, I., Bui, N. Le, Chu, D. T., Karapurkar, J. K., Jang, S. H., Chung, H. Y., Maurya, R., Alzahrani, K.

J., Ramakrishna, S., & Singh, V. (2023). Phage engineering and phage-assisted CRISPR-Cas delivery to combat multidrug-resistant pathogens. In *Bioengineering and Translational Medicine* (Vol. 8, Issue 2). John Wiley and Sons Inc. https://doi.org/10.1002/btm2.10381

Khan, Z., Khan, S. H., Mubarik, M. S., Sadia, B., & Ahmad, A. (2017). Use of TALEs and TALEN Technology for Genetic Improvement of Plants. In *Plant Molecular Biology Reporter* (Vol. 35, Issue 1). Springer New York LLC. https://doi.org/10.1007/s11105-016-0997-8

Kim, S., Hupperetz, C., Lim, S., & Kim, C. H. (2021). Genome editing of immune cells using CRISPR/Cas9. *BMB Reports*, *54*(1), 59–69. https://doi.org/10.5483/BMBRep.2021.54.1.245

Kumar, A., Yau, Y.-Y., & Kumar, V. R. (2024). CRISPR-Cas: A History of Discovery and Innovation. In *Gene Editing in Plants* (pp. 1–16). Springer Nature Singapore. https://doi.org/10.1007/978-981-99-8529-6_1

Lafountaine, J. S., Fathe, K., & Smyth, H. D. C. (2015). Delivery and therapeutic applications of gene editing technologies ZFNs, TALENs, and CRISPR/Cas9. In *International Journal of Pharmaceutics*. https://doi.org/./j.ijpharm...

Lampe, G. D., King, R. T., Halpin-Healy, T. S., Klompe, S. E., Hogan, M. I., Leo Vo, P. H., Tang, S., Chavez, A., & Sternberg, S. H. (2023). *Targeted DNA integration in human cells without double-strand breaks using CRISPR RNA-guided transposases*. https://doi.org/10.1101/2023.03.17.533036

Lewis, C. M., & Vassos, E. (2020). Polygenic risk scores: From research tools to clinical instruments. In *Genome Medicine* (Vol. 12, Issue 1). BioMed Central Ltd. https://doi.org/10.1186/s13073-020-00742-5

Li, C., Mei, H., & Hu, Y. (2020). Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy. *Briefings in Functional Genomics*, *19*(3), 175–182. https://doi.org/10.1093/bfgp/elz042

Li, H., Yang, Y., Hong, W., Huang, M., Wu, M., & Zhao, X. (2020). Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. In *Signal Transduction and Targeted Therapy* (Vol. 5, Issue 1). Springer Nature. https://doi.org/10.1038/s41392-019-0089-y

Li, T., Yang, Y., Qi, H., Cui, W., Zhang, L., Fu, X., He, X., Liu, M., Li, P. feng, & Yu, T. (2023). CRISPR/Cas9 therapeutics: progress and prospects. In *Signal Transduction and*

Targeted Therapy (Vol. 8, Issue 1). Springer Nature. https://doi.org/10.1038/s41392-023-01309-7

Liu, B., Saber, A., & Haisma, H. J. (2019). CRISPR/Cas9: a powerful tool for identification of new targets for cancer treatment. In *Drug Discovery Today* (Vol. 24, Issue 4, pp. 955–970). Elsevier Ltd. https://doi.org/10.1016/j.drudis.2019.02.011

Liu, W., Li, L., Jiang, J., Wu, M., & Lin, P. (2021). Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics. In *Precision Clinical Medicine* (Vol. 4, Issue 3, pp. 179–191). Oxford University Press. https://doi.org/10.1093/pcmedi/pbab014

Liu, Z., Shi, M., Ren, Y., Xu, H., Weng, S., Ning, W., Ge, X., Liu, L., Guo, C., Duo, M., Li, L., Li, J., & Han, X. (2023). Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy. In *Molecular Cancer* (Vol. 22, Issue 1). BioMed Central Ltd. https://doi.org/10.1186/s12943-023-01738-6

Losito, M. (2022). *Functional characterization of CRISPR-Cas interactions with DNA*.

Luan, X. R., Chen, X. L., Tang, Y. X., Zhang, J. Y., Gao, X., Ke, H. P., Lin, Z. Y., & Zhang, X. N. (2018). CRISPR/Cas9-Mediated Treatment Ameliorates the Phenotype of the Epidermolytic Palmoplantar Keratoderma-like Mouse. *Molecular Therapy Nucleic Acids*, *12*, 220–228. https://doi.org/10.1016/j.omtn.2018.05.005

Macarrón Palacios, A., Korus, P., Wilkens, B. G. C., Heshmatpour, N., & Patnaik, S. R. (2024). Revolutionizing in vivo therapy with CRISPR/Cas genome editing: breakthroughs, opportunities and challenges. In *Frontiers in Genome Editing* (Vol. 6). Frontiers Media SA. https://doi.org/10.3389/fgeed.2024.1342193

Mansoori, B., Mohammadi, A., Davudian, S., Shirjang, S., & Baradaran, B. (2017). The different mechanisms of cancer drug resistance: A brief review. In *Advanced Pharmaceutical Bulletin* (Vol. 7, Issue 3, pp. 339–348). Tabriz University of Medical Sciences. https://doi.org/10.15171/apb.2017.041

Mathur, S., & Sutton, J. (2017). Personalized medicine could transform healthcare (Review). In *Biomedical Reports* (Vol. 7, Issue 1, pp. 3–5). Spandidos Publications. https://doi.org/10.3892/br.2017.922

Mengstie, M. A., Azezew, M. T., Dejenie, T. A., Teshome, A. A., Admasu, F. T., Teklemariam, A. B., Mulu, A. T., Agidew, M. M., Adugna, D. G., Geremew, H., & Abebe, E. C. (2024). Recent Advancements in Reducing the Off-Target Effect of CRISPR-Cas9 Genome Editing. In *Biologics: Targets and Therapy* (Vol. 18, pp. 21–28). Dove Medical Press Ltd. https://doi.org/10.2147/BTT.S429411

Mengstie, M. A., & Wondimu, B. Z. (2021). Mechanism and applications of crispr/ cas-9-mediated genome editing. In *Biologics: Targets and Therapy* (Vol. 15, pp. 353–361). Dove Medical Press Ltd. https://doi.org/10.2147/BTT.S326422

Moon, S. Bin, Kim, D. Y., Ko, J. H., & Kim, Y. S. (2019). Recent advances in the CRISPR genome editing tool set. In *Experimental and Molecular Medicine* (Vol. 51, Issue 11). Springer Nature. https://doi.org/10.1038/s12276-019-0339-7

Najafi, S., Tan, S. C., Aghamiri, S., Raee, P., Ebrahimi, Z., Jahromi, Z. K., Rahmati, Y., Sadri Nahand, J., Piroozmand, A., Jajarmi, V., & Mirzaei, H. (2022). Therapeutic potentials of CRISPR-Cas genome editing technology in human viral infections. In *Biomedicine and Pharmacotherapy* (Vol. 148). Elsevier Masson s.r.l. https://doi.org/10.1016/j.biopha.2022.112743

Periwal, V. (2017). A comprehensive overview of computational resources to aid in precision genome editing with engineered nucleases. *Briefings in Bioinformatics*, *18*(4), 698–711. https://doi.org/10.1093/bib/bbw052

Rabaan, A. A., AlSaihati, H., Bukhamsin, R., Bakhrebah, M. A., Nassar, M. S., Alsaleh, A. A., Alhashem, Y. N., Bukhamseen, A. Y., Al-Ruhimy, K., Alotaibi, M., Alsubki, R. A., Alahmed, H. E., Al-Abdulhadi, S., Alhashem, F. A., Alqatari, A. A., Alsayyah, A., Farahat, R. A., Abdulal, R. H., Al-Ahmed, A. H., … Mohapatra, R. K. (2023). Application of CRISPR/Cas9 Technology in Cancer Treatment: A Future Direction. In *Current Oncology* (Vol. 30, Issue 2, pp. 1954–1976). MDPI. https://doi.org/10.3390/curroncol30020152

Rangel, N., Camargo, V., Castellanos, G., Forero-Castro, M., & Rondón-Lagos, M. (2024). Exploring the Advantages and Limitations of CRISPR-Cas in Breast Cancer. In *Gene Expression The Journal of Liver Research* (Vol. 23, Issue 2, pp. 116–126). Xia and He Publishing Inc. https://doi.org/10.14218/GE.2023.00154

Rao, G. H. R. (2022). Role of Biomolecules and Biologics in Precision Medicine, Personalized Medicine, and Emerging Therapies. In *International Journal of Biomedicine* (Vol. 12, Issue 1, pp. 70–81). International Medical Research and Development Corporation. https://doi.org/10.21103/Article12(1)_GE

Rasul, M. F., Hussen, B. M., Salihi, A., Ismael, B. S., Jalal, P. J., Zanichelli, A., Jamali, E., Baniahmad, A., Ghafouri-Fard, S., Basiri, A., & Taheri, M. (2022). Strategies to overcome the main challenges of the use of CRISPR/Cas9 as a replacement for cancer therapy. In *Molecular Cancer* (Vol. 21, Issue 1). BioMed Central Ltd. https://doi.org/10.1186/s12943-021-01487-4

Ravichandran, M., & Maddalo, D. (2023). Applications of CRISPR-Cas9 for advancing precision medicine in oncology: from target discovery to disease modeling. In *Frontiers in Genetics* (Vol. 14). Frontiers Media SA. https://doi.org/10.3389/fgene.2023.1273994

Ricroch, A., Eriksson, D., Miladinović, D., Sweet, J., Van Laere, K., & Woźniak-Gientka, E. (2024). *A Roadmap for Plant Genome Editing*.

Ryan, D. E., Taussig, D., Steinfeld, I., Phadnis, S. M., Lunstad, B. D., Singh, M., Vuong, X., Okochi, K. D., McCaffrey, R., Olesiak, M., Roy, S., Yung, C. W., Curry, B., Sampson, J. R., Bruhn, L., & Dellinger, D. J. (2018). Improving CRISPR-Cas specificity with chemical modifications in single-guide RNAs. *Nucleic Acids Research*, *46*(2), 792–803. https://doi.org/10.1093/nar/gkx1199

S. V., S., Augustine, D., Mushtaq, S., Baeshen, H. A., Ashi, H., Hassan, R. N., Alshahrani, M., & Patil, S. (2024). Revitalizing oral cancer research: Crispr-Cas9 technology the promise of genetic editing. *Frontiers in Oncology*, *14*. https://doi.org/10.3389/fonc.2024.1383062

Safari F. et al. (2017). New Developments in CRISPR Technology: Improvements in Specificity and Efficiency. *Current Pharmaceutical Biotechnology*, *18*(13), 1–17.

Saito, Y. A. (2011). The Role of Genetics in IBS. In *Gastroenterology Clinics of North America*. https://www.sciencedirect.com/science/article/abs/pii/S0889855310001354

Scholarship@western, S., Wolfs, J. M., & Edgell, D. (2017). *Dual-active genome-editing reagents*. https://ir.lib.uwo.ca/etdhttps://ir.lib.uwo.ca/etd/4546

Shinwari, Z. K., Tanveer, F., & Khalil, A. T. (2018). Ethical issues regarding crispr-mediated genome editing. *Current Issues in Molecular Biology*, *26*, 103–110. https://doi.org/10.21775/CIMB.026.103

Shirani-Bidabadi, S., Tabatabaee, A., Tavazohi, N., Hariri, A., Aref, A. R., Zarrabi, A., Casarcia, N., Bishayee, A., & Mirian, M. (2023). CRISPR technology: A versatile tool to model, screen, and reverse drug resistance in cancer. *European Journal of Cell Biology*, *102*(2). https://doi.org/10.1016/j.ejcb.2023.151299

Singh, P. (2018). *Targeted inactivation of hepatitis B virus genome using enhanced Transcription Activator-Like Effector Nucleases containing a Sharkey FokI nuclease domain*.

Singh, V., Braddick, D., & Kumar Dhar, P. (2017). *Exploring the potential of genome editing CRISPR-Cas9 technology*. https://doi.org/./j.gene...

Smith, D. J., Lunj, S., Adamson, A. D., Nagarajan, S., Smith, T. A. D., Reeves, K. J., Hoskin, P. J., & Choudhury, A. (2024). *CRISPR-Cas9 potential for identifying novel therapeutic*

targets in muscle-invasive bladder cancer. https://www.nature.com/articles/s41585-024-00901-y

Smith, T. S. (2018). *Generating Obligate Heterodimeric Transcription Activator-Like Effector Nucleases to Inactive Hepatitis B Viral Replication*.

Song, P., Zhang, Q., Xu, Z., Shi, Y., Jing, R., & Luo, D. (2024). CRISPR/Cas-based CAR-T cells: production and application. In *Biomarker Research* (Vol. 12, Issue 1). BioMed Central Ltd. https://doi.org/10.1186/s40364-024-00602-z

Tao, R., Han, X., Bai, X., Yu, J., Ma, Y., Chen, W., Zhang, D., & Li, Z. (2024). Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR/Cas9 gene editing technology. In *Frontiers in Immunology* (Vol. 15). Frontiers Media SA. https://doi.org/10.3389/fimmu.2024.1354825

Tripathi, S., Khatri, P., Fatima, Z., Pandey, R. P., & Hameed, S. (2023). A Landscape of CRISPR/Cas Technique for Emerging Viral Disease Diagnostics and Therapeutics: Progress and Prospects. In *Pathogens* (Vol. 12, Issue 1). MDPI. https://doi.org/10.3390/pathogens12010056

Vakulskas, C. A., & Behlke, M. A. (2019). Evaluation and reduction of crispr off-target cleavage events. *Nucleic Acid Therapeutics*, *29*(4), 167–174. https://doi.org/10.1089/nat.2019.0790

van Esse, H. P., Reuber, T. L., & van der Does, D. (2020). Genetic modification to improve disease resistance in crops. In *New Phytologist* (Vol. 225, Issue 1, pp. 70–86). Blackwell Publishing Ltd. https://doi.org/10.1111/nph.15967

Wang, H. X., Li, M., Lee, C. M., Chakraborty, S., Kim, H. W., Bao, G., & Leong, K. W. (2017). CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery. In *Chemical Reviews* (Vol. 117, Issue 15, pp. 9874–9906). American Chemical Society. https://doi.org/10.1021/acs.chemrev.6b00799

Wei, W., Chen, Z. N., & Wang, K. (2023). CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence. In *International Journal of Molecular Sciences* (Vol. 24, Issue 15). Multidisciplinary Digital Publishing Institute (MDPI). https://doi.org/10.3390/ijms241512317

White, M. K., & Khalili, K. (2016). CRISPR/Cas9 and cancer targets: future possibilities and present challenges. In *Oncotarget* (Vol. 7, Issue 11). www.impactjournals.com/oncotarget/

Willmann, M. R. (2020). *Genome editing for precision crop breeding*.

Xue, C., & Greene, E. C. (2021). *DNA repair pathway choices in CRISPR-Cas9 mediated genome editing*. https://www.elsevier.com/open-access/userlicense/1.0/

Yang, Y., Xu, J., Ge, S., & Lai, L. (2021). CRISPR/Cas: Advances, Limitations, and Applications for Precision Cancer Research. In *Frontiers in Medicine* (Vol. 8). Frontiers Media S.A. https://doi.org/10.3389/fmed.2021.649896

Yin, H., Sun, L., Pu, Y., Yu, J., Feng, W., Dong, C., Zhou, B., Du, D., Zhang, Y., Chen, Y., & Xu, H. (2021). Ultrasound-Controlled CRISPR/Cas9 System Augments Sonodynamic Therapy of Hepatocellular Carcinoma. *ACS Central Science*, *7*(12), 2049–2062. https://doi.org/10.1021/acscentsci.1c01143

Young, B. A. (2023). *CRISPR-Cas9 Gene Editing Tool: Potential Treatment for Sickle Cell Disease*. https://digitalcommons.sacredheart.edu/acadfest/2024/all/47

Zhang, H., Qin, C., An, C., Zheng, X., Wen, S., Chen, W., Liu, X., Lv, Z., Yang, P., Xu, W., Gao, W., & Wu, Y. (2021). Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer. In *Molecular Cancer* (Vol. 20, Issue 1). BioMed Central Ltd. https://doi.org/10.1186/s12943-021-01431-6

Zhang, L., He, W., Fu, R., Wang, S., Chen, Y., & Xu, H. (2023). Guide-specific loss of efficiency and off-target reduction with Cas9 variants. *Nucleic Acids Research*, *51*(18), 9880–9893. https://doi.org/10.1093/nar/gkad702

Zhang, W., Petri, K., Ma, J., Lee, H., Tsai, C.-L., Joung, J. K., & Yeh, J.-R. J. (2013). *Enhancing CRISPR prime editing by reducing misfolded pegRNA interactions*. https://doi.org/10.1101/2023.08.14.553324

Zhang, Z., Hou, W., & Chen, S. (2022). Updates on CRISPR-based gene editing in HIV-1/AIDS therapy. In *Virologica Sinica* (Vol. 37, Issue 1, pp. 1–10). KeAi Communications Co. https://doi.org/10.1016/j.virs.2022.01.017

Zhu, Y. (2022). Advances in CRISPR/Cas9. In *BioMed Research International* (Vol. 2022). Hindawi Limited. https://doi.org/10.1155/2022/9978571

Zischewski, J., Fischer, R., & Bortesi, L. (2017). Detection of on-target and off-target mutations generated by CRISPR/Cas9 and other sequence-specific nucleases. In *Biotechnology Advances* (Vol. 35, Issue 1, pp. 95–104). Elsevier Inc. https://doi.org/10.1016/j.biotechadv.2016.12.003